Literature DB >> 18452378

Easypod: a new electronic injection device for growth hormone.

Jovanna Dahlgren1.   

Abstract

The easypod is the first automated electronic injection device for growth hormone delivery. To save user's time and reduce administration error, the dose is preset by a physician or nurse; in addition, to allow patient adherence to be monitored, the time, date and dose (mg) of each injection is recorded. Details of the last injection and number of doses remaining in the cartridge are also displayed in order to help patients manage the injection schedule. Drug use can be optimized by splitting the dose over two cartridges, with an automatic compensation facility to avoid under-dosing. Patients can customize the depth, speed and duration of the injection. In a user trial, easypod was very well accepted. This review places easypod in the context of current and future growth hormone devices.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452378     DOI: 10.1586/17434440.5.3.297

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  12 in total

1.  Integrated Digital Health Solutions in the Management of Growth Disorders in Pediatric Patients Receiving Growth Hormone Therapy: A Retrospective Analysis.

Authors:  Vincenzo Tornincasa; David Dixon; Quentin Le Masne; Blaine Martin; Lilian Arnaud; Paula van Dommelen; Ekaterina Koledova
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-30       Impact factor: 6.055

2.  Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents.

Authors:  Mauro Bozzola; Michel Colle; Maria Halldin-Stenlid; Sylvain Larroque; Monia Zignani
Journal:  BMC Endocr Disord       Date:  2011-02-04       Impact factor: 2.763

3.  Adherence in children with growth hormone deficiency treated with r-hGH and the easypod™ device.

Authors:  S Loche; M Salerno; P Garofalo; G M Cardinale; M R Licenziati; G Citro; M Caruso Nicoletti; M Cappa; S Longobardi; M Maghnie; R Perrone
Journal:  J Endocrinol Invest       Date:  2016-07-12       Impact factor: 4.256

4.  Optimizing Patient Management and Adherence for Children Receiving Growth Hormone.

Authors:  Carlo L Acerini; Katarzyna Wac; Peter Bang; Dagmar Lehwalder
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-20       Impact factor: 5.555

5.  Analysis of real-world data on growth hormone therapy adherence using a connected injection device.

Authors:  Ekaterina Koledova; Vincenzo Tornincasa; Paula van Dommelen
Journal:  BMC Med Inform Decis Mak       Date:  2020-07-29       Impact factor: 2.796

6.  Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre.

Authors:  Maria Cristina Maggio; Beatrice Vergara; Paolo Porcelli; Giovanni Corsello
Journal:  Ital J Pediatr       Date:  2018-09-27       Impact factor: 2.638

7.  Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy.

Authors:  Jason Foo; Mohamad Maghnie; Annamaria Colao; Ioanna Vlachaki; Giorgio Colombo
Journal:  Clinicoecon Outcomes Res       Date:  2019-08-22

Review 8.  Achieving Optimal Short- and Long-term Responses to Paediatric Growth Hormone Therapy

Authors:  Jan M. Wit; Asma Deeb; Bassam Bin-Abbas; Angham Al Mutair; Ekaterina Koledova; Martin O. Savage
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-07-09

9.  Monitoring Adherence Rate to Growth Hormone Therapy and Growth Outcomes in Taiwanese Children Using Easypod Connect: Observational Study.

Authors:  Pen-Hua Su; Chen Yang; Mei-Chyn Chao; Chung-Lin Chiang
Journal:  JMIR Pediatr Parent       Date:  2021-01-15

10.  Adherence to treatment in children with growth hormone deficiency, small for gestational age and Turner syndrome in Mexico: results of the Easypod™ connect observational study (ECOS).

Authors:  A Blanco-López; C Antillón-Ferreira; E Saavedra-Castillo; M Barrientos-Pérez; H Rivero-Escalante; O Flores-Caloca; R Calzada-León; C C Rosas-Guerra; E Koledova; E Chiquete; A Ayala-Estrada
Journal:  J Endocrinol Invest       Date:  2020-04-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.